Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...
The stock's fall snapped a five-day winning streak.
The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...
Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $85.21 which represents a slight increase of $0.78 or 0.92% from the prior close of $84.43. The stock opened at ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead ...
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...
The Foster City-based biopharmaceutical company embraced a series of sustainability goals in 2021, including a commitment to ...